miR-21 modulates paclitaxel sensitivity and hypoxia-inducible factor-1α expression in human ovarian cancer cells

Oncology Letters

Volumn 6, Issue 3, 2013, Pages 795-800

  Xie, Zhongbin ^a   Cao, Liping ^b   Zhang, Jun ^c  

^a Department of Clinical Laboratory Medicine   (China)

^b Yulin Chinese Medicine Hospital   (China)

^c 3201 Hospital   (China)

Author keywords

Hypoxia inducible factor 1a; MiR 21; Ovarian cancer; Paclitaxel resistance

Indexed keywords

GLYCOPROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA; MICRORNA 21; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; SMALL INTERFERING RNA;

ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84880397014     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1432     Document Type: Article

References (23)

1. Hassan MK, Watari H, Christenson L, Bettuzzi S and Sakuragi N: Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel. Tumour Biol 32: 1031-1047, 2011.
2. McGuire WP 3rd and Markman M: Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 89 (Suppl 3): S3-S8, 2003.
3. Ozols RF and Young RC: Chemotherapy of ovarian cancer. Semin Oncol 11: 251-263, 1984.
4. Dai Z, Huang Y and Sadée W: Growth factor signaling and resistance to cancer chemotherapy. Curr Top Med Chem 4: 1347-1356, 2004.
5. Fuchs J, Habild G, Leuschner I, Schweinitz DV, Haindl J and Knop E: Paclitaxel: an effective antineoplastic agent in the treatment of xenotransplanted hepatoblastoma. Med Pediatr Oncol 32: 209-215, 1999.
6. Heney M, Alipour M, Vergidis D, et al: Effectiveness of liposomal paclitaxel against MCF-7 breast cancer cells. Can J Physiol Pharmacol 88: 1172-1180, 2010.
7. Pisters KM, Vallières E, Crowley JJ, et al: Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol 28: 1843-1849, 2010.
8. Selimovic D, Hassan M, Haikel Y and Hengge UR: Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2. Cell Signal 20: 311-322, 2008.
9. Fojo T and Menefee M: Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 18 (Suppl 5): v3-v8, 2007.
10. Roberti A, La Sala D and Cinti C: Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol 207: 571-581, 2006.
11. Leonard GD, Fojo T and Bates SE: The role of ABC transporters in clinical practice. Oncologist 8: 411-424, 2003.
12. Gottesman MM and Ling V: The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 580: 998-1009, 2006.
13. Li Z, Hu S, Wang J, et al: MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol 119: 125-130, 2010.
14. Chen C, Ridzon DA, Broomer AJ, et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179, 2005.
15. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods 25: 402-408, 2001.
16. Hu MD, Xu JC, Fan Y, Xie QC, Li Q, Zhou CX, Mao M and Yang Y: Hypoxia-inducible factor 1 promoter-induced JAB1 overexpression enhances chemotherapeutic sensitivity of lung cancer cell line A549 in an anoxic environment. Asian Pac J Cancer Prev 13: 2115-2120, 2012.
17. Bourguignon LY, Spevak CC, Wong G, Xia W and Gilad E: Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 284: 26533-26546, 2009.
18. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
19. Hilpert F, Krause G, Venhoff L, Kuhnle E, Schem C and Maass N: Epithelial ovarian cancer. Ther Umsch 64: 375-380, 2007 (In German).
20. Li H, Hui L, Xu W, et al: Triptolide modulates the sensitivity of K562/A02 cells to adriamycin by regulating miR-21 expression. Pharm Biol 50: 1233-1240, 2012.
21. Li Y, Zhu X, Gu J, et al: Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci 101: 948-954, 2010.
22. Li Y, Zhu X, Gu J, et al: Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis. Hematology 15: 215-221, 2010.
23. Nardinocchi L, Puca R and D'Orazi G: HIF-1α antagonizes p53-mediated apoptosis by triggering HIPK2 degradation. Aging (Albany NY) 3: 33-43, 2011.